J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
Correction to Lancet Oncol 2014; 15: 856. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
TL;DR: In table 2 of this Article, the “MRD response during fi rst two cycles in patients with CR or CRh” row should not have been indented, and should have been the last row in the table.
Journal ArticleDOI
Primary chemotherapy: the future for the management of advanced ovarian cancer?
TL;DR: Complete tumor cytoreduction could be achieved in a greater percentage of patients, if primary chemotherapy is used in women in whom optimal primary surgery would be difficult, and delayed surgery provides more knowledge about the biological behavior of the tumor, and this could be used to tailor treatment more effectively.
Journal Article
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
TL;DR: Olaparib is the best-studied PARP inhibitor to date, and a number of phase 3 trials with this agent are underway and the current evidence for its use, ongoing studies, future research directions, and the challenges ahead are discussed.
Journal ArticleDOI
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - A randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
Philipp Harter,Patricia Pautier,Els Van Nieuwenhuysen,Alexander Reuss,Andrés Redondo,Kristina Lindemann,Christian Kurzeder,Edgar Petru,Florian Heitz,Jalid Sehouli,Nikolaus Degregorio,Pauline Wimberger,Alexander Burges,Nadin Cron,Jonathan A. Ledermann,Domenica Lorusso,Xavier Paoletti,Frederik Marmé +17 more
TL;DR: The addition of atezolizumab to standard non-platinum combination of chemotherapy and bevacizumAB improves median overall survival from 15 to 20 months and overall survival and progression-free survival are co-primary endpoints.
Journal ArticleDOI
Clinical trials in gynecological cancer.
Edward L. Trimble,J. A Davis,Philip J. DiSaia,Keiichi Fujiwara,David K. Gaffney,Gunnar B. Kristensen,Jonathan A. Ledermann,Jacobus Pfisterer,Michael A. Quinn,Nicholas S imon Reed,Mason Schoenfeldt,J. T. Thigpen +11 more
TL;DR: This review article highlights the key clinical questions facing clinical trialists over the next decade, the information and infrastructure resources available for trials, and the methods of trial development.